KRAS and non-small cell lung carcinoma: Koyama et al.80 investigated the effect of this co-mutation in a KRAS-driven NSCLC mouse model and found that its inactivation led to aberrant cytokine production causing an increase in neutrophils, reduction in the numbers and function of tumour-infiltrating lymphocytes as well as the expression of PD-L1 in lung tumour cells.